ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Lilly Bolsters Immuno-oncology

by Lisa M. Jarvis
October 19, 2015 | APPEARED IN VOLUME 93, ISSUE 41

Eli Lilly & Co. has made two moves to bolster its immuno-oncology platform. The big pharma firm is expanding a cancer therapy collaboration established earlier this year with China’s Innovent Biologics. Lilly and Innovent will now develop up to three anti-PD-1 bispecific antibodies, which will be created by Lilly using an antibody sequence discovered by Innovent. The Chinese company will have the right to develop the drugs in China. And Lilly will add 30,000 sq ft and about 50 new jobs to its R&D center in New York City. Chemistry and lead optimization for immuno-oncology are part of the addition’s remit.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment